NOVAVAX INC (NVAX) Stock Fundamental Analysis
USA - NASDAQ:NVAX - US6700024010 - Common Stock
8.52 USD
+0.16 (+1.91%)
8.52 USD
0 (0%)
We assign a fundamental rating of 4 out of 10 to NVAX. NVAX was compared to 534 industry peers in the Biotechnology industry. There are concerns on the financial health of NVAX while its profitability can be described as average. NVAX has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year NVAX was profitable.
In the past year NVAX has reported a negative cash flow from operations.
NVAX had negative earnings in each of the past 5 years.
In the past 5 years NVAX reported 4 times negative operating cash flow.
1.2 Ratios
NVAX has a Return On Assets of 31.64%. This is amongst the best in the industry. NVAX outperforms 98.50% of its industry peers.
NVAX's Return On Equity of 1123.78% is amongst the best of the industry. NVAX outperforms 99.81% of its industry peers.
The Return On Invested Capital of NVAX (30.55%) is better than 99.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 31.64% | ||
| ROE | 1123.78% | ||
| ROIC | 30.55% |
ROA(3y)-23.82%
ROA(5y)-33.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NVAX's Profit Margin of 39.20% is amongst the best of the industry. NVAX outperforms 97.75% of its industry peers.
NVAX has a Operating Margin of 33.97%. This is amongst the best in the industry. NVAX outperforms 97.75% of its industry peers.
NVAX has a better Gross Margin (88.30%) than 89.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.97% | ||
| PM (TTM) | 39.2% | ||
| GM | 88.3% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so NVAX is creating value.
Compared to 1 year ago, NVAX has more shares outstanding
The number of shares outstanding for NVAX has been increased compared to 5 years ago.
NVAX has a worse debt/assets ratio than last year.
2.2 Solvency
NVAX has an Altman-Z score of -1.76. This is a bad value and indicates that NVAX is not financially healthy and even has some risk of bankruptcy.
NVAX has a Altman-Z score (-1.76) which is in line with its industry peers.
NVAX has a Debt/Equity ratio of 5.93. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 5.93, NVAX is doing worse than 82.40% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.93 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.76 |
ROIC/WACC3.61
WACC8.47%
2.3 Liquidity
NVAX has a Current Ratio of 2.36. This indicates that NVAX is financially healthy and has no problem in meeting its short term obligations.
NVAX's Current ratio of 2.36 is on the low side compared to the rest of the industry. NVAX is outperformed by 70.41% of its industry peers.
A Quick Ratio of 2.34 indicates that NVAX has no problem at all paying its short term obligations.
NVAX has a worse Quick ratio (2.34) than 68.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.36 | ||
| Quick Ratio | 2.34 |
3. Growth
3.1 Past
NVAX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 171.01%, which is quite impressive.
Looking at the last year, NVAX shows a quite strong growth in Revenue. The Revenue has grown by 9.22% in the last year.
NVAX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 105.31% yearly.
EPS 1Y (TTM)171.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-37.37%
Revenue 1Y (TTM)9.22%
Revenue growth 3Y-15.89%
Revenue growth 5Y105.31%
Sales Q2Q%-42.42%
3.2 Future
The Earnings Per Share is expected to grow by 17.77% on average over the next years. This is quite good.
The Revenue is expected to decrease by -9.90% on average over the next years.
EPS Next Y257.71%
EPS Next 2Y44.69%
EPS Next 3Y22.77%
EPS Next 5Y17.77%
Revenue Next Year57.45%
Revenue Next 2Y-19.09%
Revenue Next 3Y-27.87%
Revenue Next 5Y-9.9%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 4.35, the valuation of NVAX can be described as very cheap.
99.06% of the companies in the same industry are more expensive than NVAX, based on the Price/Earnings ratio.
NVAX is valuated cheaply when we compare the Price/Earnings ratio to 26.89, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 55.16, which means the current valuation is very expensive for NVAX.
89.14% of the companies in the same industry are more expensive than NVAX, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 22.99. NVAX is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.35 | ||
| Fwd PE | 55.16 |
4.2 Price Multiples
NVAX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. NVAX is cheaper than 99.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 1.57 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as NVAX's earnings are expected to grow with 22.77% in the coming years.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y44.69%
EPS Next 3Y22.77%
5. Dividend
5.1 Amount
No dividends for NVAX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
8.52
+0.16 (+1.91%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners58.63%
Inst Owner Change-0.31%
Ins Owners0.41%
Ins Owner Change5.15%
Market Cap1.38B
Revenue(TTM)1.08B
Net Income(TTM)422.82M
Analysts72.86
Price Target13.55 (59.04%)
Short Float %29.31%
Short Ratio7.8
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)483.55%
Min EPS beat(2)306.88%
Max EPS beat(2)660.22%
EPS beat(4)3
Avg EPS beat(4)228.68%
Min EPS beat(4)-58.31%
Max EPS beat(4)660.22%
EPS beat(8)5
Avg EPS beat(8)86.86%
EPS beat(12)7
Avg EPS beat(12)38.5%
EPS beat(16)7
Avg EPS beat(16)-17.35%
Revenue beat(2)2
Avg Revenue beat(2)74.3%
Min Revenue beat(2)58.52%
Max Revenue beat(2)90.08%
Revenue beat(4)4
Avg Revenue beat(4)40.88%
Min Revenue beat(4)2.61%
Max Revenue beat(4)90.08%
Revenue beat(8)5
Avg Revenue beat(8)18.46%
Revenue beat(12)7
Avg Revenue beat(12)18.88%
Revenue beat(16)7
Avg Revenue beat(16)2.76%
PT rev (1m)0%
PT rev (3m)-12.26%
EPS NQ rev (1m)23.98%
EPS NQ rev (3m)8.76%
EPS NY rev (1m)7.94%
EPS NY rev (3m)7.09%
Revenue NQ rev (1m)5.99%
Revenue NQ rev (3m)-40.38%
Revenue NY rev (1m)0.27%
Revenue NY rev (3m)3.77%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.35 | ||
| Fwd PE | 55.16 | ||
| P/S | 1.28 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 36.78 | ||
| P/tB | N/A | ||
| EV/EBITDA | 1.57 |
EPS(TTM)1.96
EY23%
EPS(NY)0.15
Fwd EY1.81%
FCF(TTM)-3.91
FCFYN/A
OCF(TTM)-3.88
OCFYN/A
SpS6.64
BVpS0.23
TBVpS-0.46
PEG (NY)0.02
PEG (5Y)N/A
Graham Number3.2
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 31.64% | ||
| ROE | 1123.78% | ||
| ROCE | 38.67% | ||
| ROIC | 30.55% | ||
| ROICexc | 86.37% | ||
| ROICexgc | 130.29% | ||
| OM | 33.97% | ||
| PM (TTM) | 39.2% | ||
| GM | 88.3% | ||
| FCFM | N/A |
ROA(3y)-23.82%
ROA(5y)-33.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.81
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.93 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.55 | ||
| Cap/Depr | 11.6% | ||
| Cap/Sales | 0.44% | ||
| Interest Coverage | 18.14 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.36 | ||
| Quick Ratio | 2.34 | ||
| Altman-Z | -1.76 |
F-Score6
WACC8.47%
ROIC/WACC3.61
Cap/Depr(3y)158.98%
Cap/Depr(5y)408.8%
Cap/Sales(3y)4.02%
Cap/Sales(5y)5.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)171.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-37.37%
EPS Next Y257.71%
EPS Next 2Y44.69%
EPS Next 3Y22.77%
EPS Next 5Y17.77%
Revenue 1Y (TTM)9.22%
Revenue growth 3Y-15.89%
Revenue growth 5Y105.31%
Sales Q2Q%-42.42%
Revenue Next Year57.45%
Revenue Next 2Y-19.09%
Revenue Next 3Y-27.87%
Revenue Next 5Y-9.9%
EBIT growth 1Y228.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year310.32%
EBIT Next 3Y13.97%
EBIT Next 5YN/A
FCF growth 1Y13.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.53%
OCF growth 3YN/A
OCF growth 5YN/A
NOVAVAX INC / NVAX FAQ
Can you provide the ChartMill fundamental rating for NOVAVAX INC?
ChartMill assigns a fundamental rating of 4 / 10 to NVAX.
Can you provide the valuation status for NOVAVAX INC?
ChartMill assigns a valuation rating of 6 / 10 to NOVAVAX INC (NVAX). This can be considered as Fairly Valued.
How profitable is NOVAVAX INC (NVAX) stock?
NOVAVAX INC (NVAX) has a profitability rating of 5 / 10.
How financially healthy is NOVAVAX INC?
The financial health rating of NOVAVAX INC (NVAX) is 3 / 10.